News
RPTX
2.810
-5.39%
-0.160
Weekly Report: what happened at RPTX last week (1111-1115)?
Weekly Report · 6d ago
Analysts' Revenue Estimates For Repare Therapeutics Inc. (NASDAQ:RPTX) Are Surging Higher
Simply Wall St · 11/13 12:01
Repare Therapeutics collaborates with U.S. National Cancer Institute
Seeking Alpha · 11/12 14:36
Repare Therapeutics announces CRADA to advance camonsertib development
TipRanks · 11/12 12:40
REPARE THERAPEUTICS ANNOUNCES AGREEMENT WITH THE US NATIONAL CANCER INSTITUTE TO ADVANCE THE DEVELOPMENT OF CAMONSERTIB
Reuters · 11/12 12:05
Morgan Stanley Sticks to Their Hold Rating for Repare Therapeutics (RPTX)
TipRanks · 11/11 13:21
Weekly Report: what happened at RPTX last week (1104-1108)?
Weekly Report · 11/11 09:19
Repare Therapeutics: Promising Oncology Advances and Financial Stability Support Buy Rating
TipRanks · 11/11 05:15
HC Wainwright & Co. Reiterates Buy on Repare Therapeutics, Maintains $10 Price Target
Benzinga · 11/08 16:36
Repare Therapeutics: Strong Financial Health and Promising Data Catalysts Justify Buy Rating with $10 Price Target
TipRanks · 11/08 15:25
Stifel Nicolaus Keeps Their Buy Rating on Repare Therapeutics (RPTX)
TipRanks · 11/08 14:46
Repare Therapeutics Reports Q3 2024 Progress and Outlook
TipRanks · 11/08 06:00
Repare Therapeutics GAAP EPS of -$0.81
Seeking Alpha · 11/07 14:31
Repare Therapeutics: Strategic Clinical Advancements and Promising Data Drive ‘Buy’ Rating
TipRanks · 11/07 14:25
REPARE THERAPEUTICS - ENTERED INTO SALES AGREEMENT RELATING TO COMMON SHARES OFFERED BY PROSPECTUS SUPPLEMENT
Reuters · 11/07 13:35
REPARE THERAPEUTICS - MAY OFFER, SELL COMMON SHARES OF UP TO $100 MLN FROM TIME TO TIME
Reuters · 11/07 13:35
Repare Therapeutics Q3 2024 GAAP EPS $(0.81) Beats $(0.83) Estimate, Cash, Cash Equivalents And Marketable Securities Were $179.4M, Expected To Fund Its Current Operational Plans Into The Second Half Of 2026
Benzinga · 11/07 12:47
BRIEF-Repare Therapeutics Q3 EPS USD -0.81
Reuters · 11/07 12:05
*Repare Therapeutics 3Q Loss/Shr 81c >RPTX
Dow Jones · 11/07 12:05
Press Release: Repare Therapeutics Provides -2-
Dow Jones · 11/07 12:05
More
Webull provides a variety of real-time RPTX stock news. You can receive the latest news about Repare Therapeutics Inc. through multiple platforms. This information may help you make smarter investment decisions.
About RPTX
Repare Therapeutics Inc. is a clinical-stage precision oncology company enabled by its proprietary synthetic lethality approach to the discovery and development of novel therapeutics. The Company utilizes its genome-wide, CRISPR-enabled SNIPRx platform to systematically discover and develop highly targeted cancer therapies focused on genomic instability, including DNA damage repair. Its pipeline includes lunresertib (RP-6306), a PKMYT1 inhibitor in Phase 1/2 clinical development; camonsertib (RP-3500), a potential Ataxia-Telangiectasia and Rad3-related protein kinase (ATR) inhibitor in Phase 1/2 clinical development; RP-1664, a Phase 1 PLK4 inhibitor; RP-3467, a preclinical polymerase theta adenosinetriphosphatase (ATPase) inhibitor program, and additional, undisclosed preclinical programs. RP-3500 is a potent and selective oral small molecule inhibitor of ATR in clinical development for the treatment of solid tumors with specific DNA damage repair-related genomic alterations.